We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

48 hedge funds and large institutions have $9.73M invested in Theriva Biologics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

0% more funds holding

Funds holding: 48 → 48 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

38% less capital invested

Capital invested by funds: $15.7M → $9.73M (-$6.01M)

Holders
48
Holders Change
–
Holders Change %
0%
% of All Funds
1.1%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
9
Reduced
5
Closed
5
Calls
$1.66M
Puts
–
Net Calls
+$1.66M
Net Calls Change
-$1.1M

Top Buyers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
+$110K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$30.4K
3
WS
Wedbush Securities
California
+$22.8K
4
UBS Group
UBS Group
Switzerland
+$19K
5
CBA
Coastal Bridge Advisors
Connecticut
+$15.2K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$145K
2
VF
Virtu Financial
New York
-$125K
3
Citadel Advisors
Citadel Advisors
Florida
-$122K
4
PPA
Parametric Portfolio Associates
Washington
-$55K
5
TSS
Two Sigma Securities
New York
-$22.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
TS
1
Third Security
Virginia
$4.21M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.49M +$30.4K +8 +2%
MP
3
MSD Partners
New York
$1.31M – – –
William Blair & Company
4
William Blair & Company
Illinois
$631K +$110K +29 +15%
6CM
5
683 Capital Management
New York
$478K – – –
BlackRock
6
BlackRock
New York
$425K -$3.8K -1 -0.7%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$196K – – –
Millennium Management
8
Millennium Management
New York
$151K -$145K -38 -41%
IA
9
IFP Advisors
Florida
$83K – – –
UBS Group
10
UBS Group
Switzerland
$69K +$19K +5 +25%
LTFS
11
Ladenburg Thalmann Financial Services
Florida
$58K – – –
Creative Planning
12
Creative Planning
Kansas
$56K – – –
Northern Trust
13
Northern Trust
Illinois
$55K – – –
Fisher Asset Management
14
Fisher Asset Management
Washington
$43K – – –
WS
15
Wedbush Securities
California
$42K +$22.8K +6 +67%
FSA
16
Franklin Street Advisors
North Carolina
$40K – – –
California Public Employees Retirement System
17
California Public Employees Retirement System
California
$32K – – –
SAM
18
Scopus Asset Management
New York
$32K – – –
SBIA
19
Sheaff Brock Investment Advisors
Indiana
$32K – – –
VCM
20
Vivaldi Capital Management
Illinois
$32K – – –
Jacobs Levy Equity Management
21
Jacobs Levy Equity Management
New Jersey
$31K – – –
Bank of New York Mellon
22
Bank of New York Mellon
New York
$31K +$7.61K +2 +22%
SLG
23
Stanley-Laman Group
Pennsylvania
$19K – – –
BA
24
Bard Associates
Illinois
$18K – – –
State Street
25
State Street
Massachusetts
$17K – – –
1
2 3

TOVX Hedge Fund Activity: Q1 2018 in Review

48 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q1 2018, worth a combined $9.73M — down 38% from $15.7M a quarter earlier.

Fund positioning in TOVX was balanced in Q1 2018: 5 funds opened new positions, 5 closed out, 9 added to existing stakes and 5 trimmed.

The largest buyer was William Blair & Company, adding an estimated $110K. The largest seller was Millennium Management, cutting an estimated $145K.

  • 48 institutional investors held Theriva Biologics (TOVX) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $9.73M of Theriva Biologics stock for Q1 2018, down 38% quarter-over-quarter.
  • 5 funds opened new Theriva Biologics positions in Q1 2018 and 5 closed out, a net change of 0 holders.
  • The largest Theriva Biologics buyer in Q1 2018 was William Blair & Company, an estimated $110K added.
  • The largest Theriva Biologics seller in Q1 2018 was Millennium Management, an estimated $145K sold.

Based on aggregated 13F filings for Q1 2018.